Thyroid disorders as predictors of cemiplimab efficacy in recurrent/metastatic cervical cancer: real-world evidence from Poland
Ir-thyroid disorders may indicate enhanced immune activation and represent a potential surrogate of cemiplimab efficacy in r/mCC, although validation in larger cohorts is required.
Authors
- Renata Pacholczak‐Madej (ORCID: https://orcid.org/0000-0002-6535-4841)
- Maja Lisik-Habib
- Radosław Mądry (ORCID: https://orcid.org/0000-0003-0738-2788)
- Zuzanna Borysiewicz
- Wiktor Szatkowski (ORCID: https://orcid.org/0000-0001-7682-7176)
- Paweł Blecharz (ORCID: https://orcid.org/0000-0001-5310-0054)
- Jerzy Jakubowicz (ORCID: https://orcid.org/0000-0003-4804-8591)
- Monika Szarszewska (ORCID: https://orcid.org/0000-0002-7101-1909)
- Mirosława Püsküllüoğlu (ORCID: https://orcid.org/0000-0002-2647-9625)
- Ewa Iwańska
- Katarzyna Gabalewicz
Institutions
- Poznan University of Medical Sciences (PL)
- Jagiellonian University (PL)
- State University of Applied Sciences in Elbląg (PL)
- Copernicus Memorial Hospital (PL)
- National Institute of Oncology (HU)
- Lublin Oncology Center (PL)
- University of Life Sciences in Poznań (PL)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-06-20
- DOI
- https://doi.org/10.3389/fimmu.2025.1604826
- Citations
- 4
- Primary Topic
- Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.18